


Royal Jelly—A Traditional and Natural Remedy for Postmenopausal Symptoms and Aging-Related Pathologies

Women's life stages are based on their reproductive cycle. This cycle begins with menstruation and ends with menopause. Aging is a natural phenomenon that affects all humans, and it is associated with a decrease in the overall function of the organism. In women, aging is related with and starts with menopause. Also, during menopause and postmenopausal period, the risk of various age-related diseases and complaints is higher. For this reason, researchers were pushed to find effective remedies that could promote healthy aging and extended lifespan. Apitherapy is a type of alternative medicine that uses natural products from honeybees, such as honey, propolis, **royal jelly**, etc. **Royal jelly** is a natural yellowish-white substance, secreted by both hypopharyngeal and mandibular glands of nurse bees, usually used to feed the queen bees and young worker larvae. Over the centuries, this natural product was considered a **gold mine for traditional and natural medicine, due to its miraculous effects.** **Royal jelly** has been used for a long time in commercial medical products. It has been demonstrated to possess a wide range of functional properties, such as: **antibacterial, anti-inflammatory, vasodilative, hypotensive, anticancer, estrogen-like, antihypercholesterolemic, and antioxidant activities.** This product is usually used to supplement various diseases such as **cardiovascular disease, Alzheimer's disease, sexual dysfunctions, diabetes or cancer.** The main objective of this study is to highlight the effectiveness of **royal jelly** supplementation in **relieving menopause symptoms and aging-related diseases.** We also aimed to review the most recent research advances regarding the composition of **royal jelly** for a better understanding of the effects on human health promotion.





1. Introduction

Menopause represents a transitional phase into a woman's life, during which a wide range of changes in metabolism, physiology, mental, and physical well-being occur [1]. Menopausal symptoms usually have a **significant negative impact** on the overall quality of life and become a psychosocial impairment. The majority of these symptoms are a consequence of estrogen withdrawal or a prolonged estrogen deficiency [2]. Post-menopausal women are at **increased risk of atherosclerosis, cardiovascular events, diabetes, mood disorders such as anxiety and depression, vasomotor symptoms (hot flushes, night sweats) osteoporosis and vaginal atrophy** [3]. Conventionally, these problems are treated with hormonal replacement therapy but the risk of **undesirable adverse effects such as breast cancer**, abnormal uterine bleeding or breast tenderness sometimes outweighs the benefits, which is why more natural alternatives tend to be used [4,5]. Natural therapies for menopausal-related symptoms and complaints include phytoestrogens, which are natural molecules similar to human estrogens, considered to prevent postmenopausal symptoms. Soybeans and **red clover** are the most well-known natural alternatives to conventional hormone replacement therapy, but their efficiency is still highly debated [6].

Apitherapy is a type of **alternative medicine** that uses natural products from honeybees, such as honey, propolis, **royal jelly**, bee bread, and bee venom, whose healing properties are described by centuries [7]. These products also demonstrated their usefulness for the treatment of postmenopausal complaints. **Royal jelly, known as "superfood"**, is a creamy substance secreted by the mandibular and hypopharyngeal glands of nurse bees, used to feed the queen bees throughout their lifetime and worker bees during the stage of larvae [8]. The consumption of this magical liquid by the queen bees generate many advantages such as their size, which is double in comparison to worker bees, a longer lifespan and a better function of their reproductive system [9]. In the last years, the production of **royal jelly** in China considerably increased because beekeepers developed a genetic selection of high-producing **royal jelly** Italian bees [10]. China became the largest producer of royal jelly, and nowadays it possesses almost 90% of all world production. Annually, more than 4000 tons of **royal jelly** are produced and exported from China to the United States or Europe [11,12].

Although there are many medical records of the usage of **royal jelly** all over the world, it has been mainly used in Asia. Recent reports indicated a high potential of this natural product to improve human health. **Royal jelly's pharmaceutical properties**, from animal models to humans, have been widely investigated. Despite the mechanisms of action are still under research, it attracted the attention of many investigators around the world. **Royal jelly improves the reproductive health, neurologic diseases, and possesses several biological properties, such as: antibacterial, vasodilative, anti-inflammatory, hypotensive, anticancer, estrogen-like, antihypercholesterolemic, and antioxidant effects** [13]. In the last years, royal jelly was reported as a valuable medicinal agent [7,14] **for healthy aging and longevity** [15].

In this article, we focus on the studies regarding the biological effects of **royal jelly** during menopause, and on its mechanisms of action. We aim to bring together all these studies in order to have a better understanding of whether and how royal jelly could be a natural remedy for menopausal complaints and aging-related diseases. **Figure 1** illustrates the main biological effects of royal jelly.

2. Chemical Composition of Royal Jelly

Royal jelly is a rich source of proteins, **peptides**, sugars, fatty acids, and other bioactive substances. Its variation generally depends on the biodiversity of the flora, characteristic of each geographic area [16], and the seasonal conditions of feeding. The water content of royal jelly

represents 60–70% from the final composition. Royal jelly is an acid liquid and its pH ranges between 3.6 and 4.2 [17].

2.1. *Proteins and Peptides*

Proteins represent, after water, the most dominant components of royal jelly. Almost 50% for the final composition are proteins and various peptides. From these, 80–90% are MRJPs (major royal jelly proteins), also known as apalbumins [18]. MRJPs represent a family of nine major proteins, with molecular weights ranging between 49 and 87 kDa. They are termed MRJP1-MRJP9 and are encoded by nine different genes [19].

MRJP1 is the most dominant among all the major proteins family. It contains a monomeric glycoprotein known as royalactin, which activates p70 S6 kinase. **This kinase is responsible for the increase of the juvenile hormone levels, essential for the normal development and function of the ovaries** [20].

Most of the health and metabolic benefits of the royal jelly are due to the glycosylated proteins from its composition [21,22]. MRJPs family is not the only proteic compound of royal jelly. It contains in small amounts **peptides such as aspimin, royalisine and jelleines (jelleines-I to jelleines-IV)** [23]. From these, royalisine and jelleines exert **antimicrobial effects and enhance the efficiency of the immune response to common infections.**

2.2. *Amino Acids*

Royal jelly contains a wide amount of amino acids, especially essential amino acids [24]. The most expressed free amino acid from royal jelly is lysine (62.43 mg/100 g). This is followed by various quantities of cysteine, proline, and aspartic acid. Recent research [25] showed that long-term dietary supplementation of leucine, isoleucine and valine extracted from royal jelly, enhances the expression of sirtuin 1, mitochondrial biogenesis and reduces the production of reactive oxygen species (ROS) in the skeletal muscles and myocardium. In these conditions, royal jelly administration as a dietary supplement can alleviate age-related muscle dysfunctions.

2.3. *Sugars*

Carbohydrates represent almost 15% of the total composition of royal jelly [26]. The main sugars are glucose and fructose, and together represent almost 90% of the final composition. Depending on the beekeeping foods, botanical origin, season, and bee species, glucose may reach almost 50–70% of the total sugars, while sucrose only accounts for 0.8–3.6%. Other small amounts of oligosaccharides such as erlose, trehalose, ribose, raffinose, gentiobiose or melibiose may be found in royal jelly composition [27].

2.4. *Lipids and Fatty Acids*

Lipids represent between 7% and 18% of the content of royal jelly, and 80–85% of these are dicarboxylic acids and hydroxy fatty acids [28]. The most common fatty acids from royal jelly are 10-hydroxy-2-decenoic acid (10H2DA), sebacic acid (SA) and 10-hydroxydecanoic acid (10-HDA). 10-HDA represents 3,5% of freeze-dried royal jelly composition and it is the most stable compound [29]. Moreover, it acts like a potent antibacterial agent that protects bee larvae against bacterial infections from the bee hives [30].

10-HDA was reported as a potent inhibitory agent of matrix metalloproteinases (MMPs), which contribute to tisular aging and cause several inflammatory diseases such as arthritis. SA, 10-HDA, and 10H2DA are able to mediate estrogen signaling by increasing the activity of the estrogen receptors (ER). Suzuki et al. [31] reported that several lipidic compounds isolated from royal jelly (trans-2-decenoic acid, 10-hydroxy-trans-2-decenoic acid, 10-HDA, and 24-methylenecholesterol)

inhibited the binding of 17 β -estradiol to ER β . However, they exerted no effect on the binding to ER α . These findings provide strong evidence concerning the estrogenic effect of royal jelly compounds.

2.5. Other Constituents: Vitamins, Minerals, Acetylcholine, Polyphenols

Vitamins and minerals represent 0.8–3% of royal jelly fresh matter. The most abundant vitamin from the composition of royal jelly is vitamin B₅, followed by niacin and small amounts of vitamin A, C, E, and vitamin B₁, B₂, B₆, B₈, B₉, and B₁₂ [17]. The major minerals are K, Ca, Na, Mg, Zn, Fe, Cu and Mn, in this descending order. Royal jelly also contains trace elements such as Co, Hb, Ba, W, Cr, Ni, V, Pb, Mo, whose concentrations are highly constant [32].

Royal jelly also contains nucleotides (e.g., guanosine, adenosine, and uridine) and phosphates, such as adenosine monophosphate, adenosine diphosphate, and adenosine triphosphate. Adenosine N1-oxide is an oxidized molecule of the adenosine [33,34], which demonstrated its neurogenic effects and its tropism for the central nervous system. It stimulates neurite outgrowth by inducing PC12 cells differentiation into neural cells [34] and contribute to a normal neuronal development [33]. Acetylcholine, which is known as a neurotransmitter, can also be found in royal jelly composition (1 mg/g dry weight). Its consumption may prevent the development of neurogenerative dysfunctions, such as Alzheimer's disease [35].

The flavonoids described in royal jelly can be divided into the following five categories: isoflavonoids (genistein and formononetin), flavones (apigenin, chrysin and luteolin), flavonols (kaempferol), flavonones (hesperetin, naringerin, isosakuranetin) and isoflavonoids (genistein, formononetin). The phenolic content of royal jelly is based on organic acids such as octanoic or dodecanoic acid and pinobanksin [36]. Figure 2 illustrates a schematical representation of the royal jelly composition and the main functional activities of its compounds.

Figure 2. Schematical representation of the biological composition of royal jelly and the main functional activities of the compounds [37,38,39,40,41,42,43].

3. Studies of Royal Jelly as a Beneficial Therapeutic Agent for Postmenopausal Symptoms and Aging-Related Diseases

Hormone replacement therapy is the most common treatment used by the majority of women in order to decrease postmenopausal symptomatology and to improve their quality of life during this period. The most significant disadvantage of this type of treatment is the multitude of side effects, which is why replacing it with natural alternatives has been emphasized. Using nonhormonal methods in order to decrease menopause-related symptoms and to treat various pathologies is known as complementary medicine. It consists of the administration of herbal products, phytoestrogens or food supplements [44].

Royal jelly is a traditional and natural product that, due to its similarity with estrogens [45] is used by postmenopausal women for the improvement and treatment of menopause-related complications and aging-related pathologies. The effects of royal jelly during menopause represent an actual subject and many studies were conducted on this topic. Unfortunately, there is only a small amount of human clinical trials and the main majority of the investigations were realized on ovariectomized animal models.

3.1. Estrogen-like Activity

Royal jelly has shown its estrogenic effect both in vitro and in vivo. This effect is mediated through the interaction with estrogenic receptors (ER). Daily administration of royal jelly endorsed

ovarian hormones and follicular development in a rat model and improved the fertility parameters. **Royal jelly** also improved the oocyte maturation, ameliorated redox status and activated glucose pathways in cumulus oophorus [46]. Besides, a recent study [47] showed that **royal jelly** administration, in conjunction with exogenous progesterone, similarly increased the pregnancy rate and the estrogenic response in Awassi ewes.

Luteinizing hormone (LH) and folliculo-stimulant hormone (FSH) are gonadal hormones involved in reproduction. Their levels are under estrogen and inhibin control. In addition, these hormones are involved in the natural aging process. In young women, the high amounts of estrogen maintain FSH and LH decreased. In menopause, the reduction of the follicular size, associated with luteal regression, affects the regular release of estrogen and inhibin, leading to abnormal secretion of FSH. The supplemental dietary consumption of **royal jelly** was reported very useful in this process, due to its content of fatty acids, especially 10-hydroxyl-2-decenoic acid. This compound increases the synthesis of estrogens and maintains low levels of serum FSH and LH. Furthermore, 10-hydroxyl-2-decenoic acid is **very efficient in preventing aging-related follicular depletion and enhancing hormonal regulation** [48].

The research on ovariectomized rats showed that **royal jelly** competes with E2 for binding ER α and ER β , but its affinity is weaker in comparison to phytoestrogens or diethylstilbestrol. Also, **royal jelly** may restore VEGF expression in the uterus by increasing gene transcription in MCF-7 cells, while 20 mg/kg of 17 β -estradiol may restore the expression of this factor in both uterus and brain [45].

- ✓ Clinical studies showed that the oral administration of **royal jelly (1 g/day)** is able to **decrease the severity of the premenstrual syndrome and to improve the quality of life in reproductive-aged women** [49]. In addition, during menopause and in the postmenopausal period, **royal jelly** improves genito-urinary syndrome, which is one of the most common complaints of women during these periods [50].

One of the goals of **royal jelly supplementation** is to **improve the quality of life during postmenopausal period**. Sharif et al. [51] carried out a study using a cohort of 200 women aged between 45 and 60 years old. Each subject received either capsules of **royal jelly (1 g daily)** or placebo, during a period of 2 months and the results were compared. The investigators observed that after 8 weeks of **royal jelly** intake, the menopausal score recorded a significant decrease in comparison with the placebo group. Therefore, **royal jelly can alleviate postmenopausal symptoms such as hot flushes, night sweats, and other menopause-related complaints**, but the research results on this topic are still inconsistent.

The quality of life during menopause is also disturbed by urinary incontinence or vulvovaginal atrophy, both known as **genitourinary syndrome**. These complications adversely impact the psychosocial and partner relationships of the postmenopausal women. In order to observe the therapeutic effects of **royal jelly** for the amelioration of vulvovaginal atrophy, 90 postmenopausal women were randomly distributed to receive **vaginal cream of royal jelly**, conjugated estrogens or lubricant during a period of 12 weeks [50]. After this period, the vaginal cytology was evaluated among with the quality of life score. The results showed an improvement in the quality of life score of the first group, which received **vaginal royal jelly cream**. Regarding the vaginal cytology, the Pap smear test showed better results in the group treated with topic estrogens, in comparison with the other two cohorts.

During menopause, sudden estrogen level withdrawal affects the autonomic nervous system, leading to the development of neurodegenerative diseases (e.g., **Alzheimer disease**), **mood disorders** (e.g., **anxiety, depression**) or **headache, low back pain or backache**. 42

postmenopausal women accusing anxiety, backache and low back pain were recruited and randomly received either 800 mg of dextrin or 800 mg of enzyme-treated royal jelly, for 3 months [52]. After this period, both anxiety score and backache score in royal jelly group were significantly decreased compared to placebo group. Moreover, **no side effects** were reported during the administration of enzyme-treated royal jelly.

3.2. **Anticancer Activity**

Other beneficial effects of royal jelly consists of the **inhibition of tumoral cells growth**, tumor-related angiogenesis and activation of immune functions. Cancer is a common pathology in elderly population, and cancer-related fatigue is a complication that further decreases the quality of life of these patients. In these cases, complementary medicine can be a valuable choice in order to ameliorate the symptoms with a minimum of side effects. According to Mofid et al. [53], up to 50% of cancer patients experience cancer-related fatigue, and the **administration of both royal jelly and processed honey can alleviate the symptomatology**. They administered **5mL of royal jelly and processed honey twice daily** to 26 patients, and compared the results with those obtained by 26 patients, which received only 5 mL of honey, under the same scheme, for one month. The conclusion of this clinical trial was that the supplementation of **honey intake with royal jelly** is more effective for the amelioration of cancer-related fatigue.

In women, the most common cancers are gynecological cancers. **In menopause, the most prevalent is breast cancer** and royal jelly demonstrated its ability as a complementary therapy in cancer. Bisphenol A (BPA) is one of the most widespread chemicals worldwide, which possesses a structural similarity with estrogens. This characteristic allows BPA to strongly bind to human estrogen-related receptor γ (ERR γ) [54]. In these conditions, BPA is a risk factor for breast cancer in a time-depending and dose-depending manner. Nakaya et al. [55] reported that royal jelly inhibited the growth-promoting effect of BPA in vitro, using MCF-7 cell lines. In the absence of BPA, royal jelly did not affect cellular proliferation.

RJP₃₀ is a fraction of royal jelly obtained by precipitation with ammonium sulfate. In vitro, this faction was cytotoxic for human cervical carcinoma cells (HeLa cell line). After only 7 days to the first administration, the cellular density decreased approximately 2,5 fold [56]. Shirzad et al. [57] inoculated tumor cells in 28 male Balb/c mice and after the inoculation, animals orally received various doses of royal jelly (100, 200 or 300 mg/kg). The tumor size was measured every 2 days from the fifth day, and the investigators observed a significant decrease in tumor size.

3.3. *Hypocholesterolaemiant Effects*

Menopause is a period associated with a high risk for cardiovascular diseases. The main risk factor for the development of cardiovascular pathology is represented by dyslipidemia. Being rich in fatty acids with hypolipidemic properties, royal jelly is used in postmenopausal population in order to restore the balance of the lipidic profile. Despite royal jelly is a potent hypocholesterolaemic and hypolipidaemic agent, its active compounds that lowers the cholesterol levels and the mechanisms of action are still to be discovered. MRJP1 exerts the most potent hypocholesterolaemic effects [43]. MRJP1 interacts with bile acids and enhances the excretion of fecal bile acids. It also induces an increased tendency for fecal excretion of the cholesterol. This major protein of royal jelly also enhances the hepatic cholesterol catabolism. Another hypocholesterolaemiant mechanism of royal jelly consists of the increase of low-density lipoprotein receptor (LDLR) gene expression. This molecule regulates the cholesterol incorporation into the liver. Furthermore, royal jelly decreased gene expression of squalene epoxidase and sterol regulatory element-binding protein in mice, which are the key factors for cholesterol biosynthesis [58].

Lambrinoudaki et al. [59] included 36 postmenopausal individuals in a prospective study and analyzed their circulating cardiovascular risk markers and bone turnover parameters after three months of daily administration of 150 mg royal jelly. No significant changes were recorded in the bone turnover parameters or in the circulating cardiovascular risk markers (protein S, protein C, antithrombin-III and Plasminogen Activator Inhibitor-1). However, significant changes were recorded in terms of the lipid profile. After daily intake of royal jelly, the values of (high-density lipoprotein cholesterol) HDL-C increased, while (low-density lipoprotein cholesterol) LDL-C and total cholesterol (TC) significantly decreased. Therefore, royal jelly supplementation may offer a valuable alternative method of balancing menopause-related dyslipidemic disorders.

In healthy volunteers, the daily intake of royal jelly (6 g/day during 4 weeks) resulted in a significant decrease of LDL-C and TC. No significant differences were observed between cases and controls regarding serum concentrations of HDL-C and TG [60]. A recent meta-analysis [61] reported that royal jelly reduced TC and increased HDL-C serum levels in studies with a long-term follow-up period. The same study mentioned that TG and LDL-C levels were not significantly improved.

These findings suggest that this natural product may play an important role in cardiovascular health protection by ameliorating the harmful effects of increased cholesterol.

3.4. Anti-Hypertensive Effects

Hypertension is one of the most common cardiovascular risk factors in elderly population. It may cause myocardial infarction, heart failure, cerebral stroke, and it is usually associated with metabolic syndrome. Three peptides contained in royal jelly (Ile-Val-Tyr, Val-Tyr, and Ile-Tyr) were reported to inhibit the activity of angiotensin I-converting enzyme and to normalize the systolic blood pressure after only 28 days of treatment in hypertensive rats [62].

Anti-hypertensive and vasodilative effects of royal jelly were studied on hypertensive rats and isolated rabbit thoracic aorta rings [63]. Royal jelly reduced systolic and diastolic blood pressure and increased NO levels in vivo. Furthermore, royal jelly produced vasodilation in isolated rabbit aorta rings. In addition, royal jelly increased the production of nitric oxide (NO) TC and cyclic guanosine monophosphate (cGMP) levels in the aortic rings. In conclusion, anti-hypertensive effects of royal jelly are linked by NO production, and vasodilation is secondary to muscarinic receptor agonists action via NO/cGMP pathway.

3.5. Effects on Bone Metabolism

During menopause, bone turnover parameters are usually modified, and osteoporosis is one of the most common menopause-related complications. Bisphosphonates represent the gold standard treatment for postmenopausal osteoporosis. These agents possess a high affinity for bone minerals and bind to hydroxyapatite crystals encountered on the bony surfaces. Their effects consist of the down-regulation of bone resorption mediated by osteoclasts [64]. Royal jelly is a natural alternative used for the prevention of osteoporosis and for the improvement of bone strength and several studies on this topic were realized using animal models.

Royal jelly was administered to ovariectomized rats daily for 3 months, in order to analyze its effects on bone metabolism [65]. After this period, it was reported that femur bone mineral density was not significantly improved. However, the femur stiffness was higher in the study group in comparison to the control group, suggesting that royal jelly cannot prevent the apparition of menopause-related osteoporosis, but it can improve the strength of the bone.

In contradiction with these results, another study [66] sustained that both enzyme-treated **royal jelly** and **royal jelly** may prevent osteoporosis. The explanation consists of the enhancing of intestinal calcium absorption. Hidaka et al. administered 17 β -estradiol or **royal jelly** to ovariectomized rats. Their findings showed that **royal jelly is almost as effective as hormone replacement therapy in preventing osteoporosis**. Furthermore, using a mouse marrow culture model, it was highlighted the inability of **royal jelly** to inhibit calcium loss induced by the parathyroid hormone and the development of osteoclast-like cells, induced by the same hormone.

3.6. Anti-Aging Effects

Royal jelly consumption is associated with an increase in the lifespan of bees and other species. This natural product can delay the apparition of natural aging and some age-related disorders. Furthermore, it has been demonstrated that **royal jelly** can promote longevity and is useful to improve the quality of life during aging through its components [67]. Proteins and lipids from **royal jelly** can extend the lifespan of various species, such as honeybees, nematodes, crickets or mice. Xin et al. [68] reported that MRJPs increased the longevity of *Drosophila melanogaster* through the promotion of the pathway mediated by the anti-epidermal growth factor receptor. Moreover, royalactin exerted the same effects on *Caenorhabditis elegans*, by promoting EGF (epidermal growth factor) and EGFR (epidermal growth factor receptor) signaling pathways [69].

Regarding the effects on lifespan extending in mice, studies have shown that long-term intragastric administration of **royal jelly** prevented aging-related weight loss, improved memory, and delayed aging-related atrophy of the thymus [70]. In addition, the physical performance of the treated animals was better in comparison to the control group: makers of **muscle stem cells increased** and muscular atrophy was lowered [70]. Furthermore, **royal jelly** could significantly delay age-related motor functions [67].

Lipid components of **royal jelly** were reported to **inhibit the natural aging process in human cell cultures** by two mechanisms: up-regulation of EGF signaling and down-regulation of insulin-like growth factors (IGF) [15]. 10-HDA is the primary lipid compound of **royal jelly**, and it has been shown to increase the lifespan of *Caenorhabditis elegans* by dietary restriction signaling and TOR components [71]. An interesting question is whether the effects of royal jelly observed on animal model organisms can be extended to humans. Despite there is a small number of studies in this field, the results indicated that **anti-aging activity of royal jelly** and its compounds on human cell lines, supports previous results reported for model organisms. It has been demonstrated that **royal jelly** and its special lipidic compound 10-HDA can decrease cellular senescence, and can stimulate the production of procollagen type I and transforming growth factor- β 1 (TGF- β 1) [72,73]. Moreover, a recent study [74] using human fibroblast cells showed that MRJPs induce higher cellular proliferation, longer telomeres and decreased senescence.

The skin is the largest organ of the body. During menopause and natural aging process, it is affected by the estrogen level withdrawal. Beside, changes in the skin collagen levels leads to a degreased skin elasticity and strength [75]. **Royal jelly has been reported as a protective agent against skin aging that acts by enhancing collagen production** in ovariectomized rats [76]. It was reported that after the administration of royal jelly 1% to estrogen-deprived females of Sprague-Dawley rats, the level of procollagen type I protein increased in the skin of the animals. Furthermore, the level of recovered collagen was very close to the normal amounts. In conclusion, **royal jelly can be considered a valuable and effective dietary supplement against the natural aging process of the skin in postmenopausal period, but future clinical trials on humans are definitely required.**

3.7. Neuroprotective Effects

Menopause represents a normal milestone that associates a wide range of hormonal changes. In this context, several neurologic illnesses may develop and usually severely impact the psychosocial life of postmenopausal women [77]. Anxiety, depression, or spatial memory loss are some of the most frequent complaints of postmenopausal women. In order to investigate the effects of royal jelly on neurologic disorders, several studies were conducted on animal models.

Due to the aging process, poor mental performance state and neurodegenerative diseases such as Alzheimer's disease are the most common among the elderly. Royal jelly seems to stimulate the mental functions through its neuroprotective effect. Daily intake of royal jelly was reported to consolidate the memory abilities and learning skills in honeybees and rats [78]. Furthermore, this natural product stimulates neurite outgrowth, induces the regeneration of hippocampal granule cells, and protects the central nervous system against oxidative injuries [33,79].

Royal jelly intake is efficient for the alleviation of menopause-related neurological disorders, but the mechanisms of action remain to be better described. However, the decrease of cholesterol and beta-amyloid levels, the increase of estrogen levels, and the improvement of blood-brain barrier seem to be the most mentioned mechanisms by which royal jelly exerts its neuroprotective role [34]. Zhang et al. [80] showed that purified royal jelly peptides might inhibit β -amyloid 40 and 42 through the regulation of beta-secretase, being useful in ameliorating diseases such as Alzheimer's disease. Moreover, royal jelly improved the structural image of the brain and behavioral dysfunctions in cholesterol feed rabbits. It acted through the decrease of body weight, lipid, beta-amyloid and acetyl-cholinesterase levels, associated with the increase of choline acetyltransferase into the brain [80].

Pyrzanowska et al. [81] showed that Greek royal jelly was able to improve the memory performance in aged Wistar rats. They administered to the animals 50 or 100 mg of royal jelly powder/kg twice daily, by gastric gavage, for 8 weeks. After this period, a significant improvement in the memory performance was observed in rats treated with 50 mg powder/kg in comparison to controls. Another study [82] evaluated spatial memory and depression-like behaviors in ovariectomized rats after 82 days of royal jelly ingestion. This natural product improved memory performances and depression-like behaviors. Besides, brain weight and myelin galactolipids slightly increased after royal jelly intake, in comparison to hormone replacement therapy.

3.8. Anti-Diabetic Effects

Diabetes mellitus is a very common pathology in the postmenopausal women. In the last years, novel dietary supplements with major therapeutic benefits and a minimum of adverse effects were investigated for the therapeutic management of these patients. In healthy individuals, royal jelly significantly decreased serum glucose levels and increased insulin concentration [83].

Yoshida et al. [84] recently performed a study on obese KK-Ay mice, with type 2 diabetes. 10 mg/kg of royal jelly were administered by oral gavage. Insulin levels, body weight and plasma glucose were analyzed after 4 weeks of daily treatment. The results indicated a partially suppressed body weight associated with decreased glycemia in the study group. However, insulin resistance was not improved. The explanation consists of the suppression of gluconeogenesis by royal jelly, through the decrease of glucose-6-phosphatase mRNA expression. Furthermore, this natural product induced the expression of adiponectin receptor-1, adiponectin, and phosphorylated AMP-activated protein kinase, which generated the suppression of glucose-6-phosphatase, an essential enzyme for gluconeogenesis. Unlike the results obtained by Yoshida et al. [84], who do not mention the decrease in insulin resistance among the effects of royal jelly, Zamami et al. [85] suggested that this dietary supplement could be very effective to prevent insulin resistance. After 8 weeks of daily administration

in doses of 100 mg/kg or 300 mg/kg, plasmatic levels of TG and insulin significantly decreased, and systolic blood pressure tended to decrease in ovariectomized rats.

Thirty two male Wistar rats with streptozocin-induced diabetes received 100 mg of royal jelly/kg body weight daily [86]. After six weeks, the urinary levels of urea, creatinine, uric acid, albumin, and histopathological findings of kidneys and liver tissues were significantly improved. Moreover, royal jelly significantly improved the levels of TG, LDL-C, HDL-C, VLDL-C, total cholesterol and ApoA-1 in diabetic subjects, thereby promoting the glycemic balance [87].

Given all the presented studies and findings, we can consider royal jelly a golden dietary supplement, which can be used to alleviate postmenopausal symptoms and to treat a wide range of aging-related pathologies. However, further human clinical trials are necessary in order to better observe beneficial effects, molecular mechanisms of actions and potential side effects of this valuable natural and traditional product. In **Table 1** and **Table 2**, we separately summarized the studies conducted on humans and animals/cells cultures in the last 20 years, in order to investigate the efficiency of royal jelly as a remedy for postmenopausal problems and complications.

Table 1. Human studies regarding beneficial effects of royal jelly in menopause.

Table 2. Studies regarding beneficial effects of royal jelly in menopause using animal models and cellular lines.

Figure 3 is a schematic representation of the royal jelly's beneficial effects in relieving menopause symptoms and aging-related diseases.

Figure 3. Royal jelly's beneficial effects in relieving menopause symptoms and aging-related diseases. This figure also illustrates the essential pathways through which royal jelly exerts its estrogen-like action, one of the most important characteristics of this natural product.

4. Side Effects of Royal Jelly

Royal jelly is a natural product widely consumed worldwide. However, several side effects of its consumption have been described. The major allergens of this product are MRPJ 1 and MRPJ2 [100], and these are common with honeybee venom allergens. MRJPs can cause several allergic reactions such as asthma, dermatitis, skin rashes, eczemas, bronchospasm, anaphylaxis, hemorrhagic colitis [101], or even anaphylactic shock and death, in some situations [102]. A positive diagnosis of royal jelly anaphylaxis is established based on a positive prick test and systemic clinical symptoms. Oral allergy syndrome secondary to royal jelly intake has also been mentioned in the literature [103].

No reports regarding the possible interactions between royal jelly supplements and other drugs concomitantly taken were made. However, Lee et al. [104] presented the case of an 87-years-old man with long-term warfarin therapy, supplemented with royal jelly capsules. He referred to the hospital for hematuria, and the most probable explanation for his symptoms was a possible interaction between warfarin and royal jelly. For this reason, clinicians should repeatedly inform their patients regarding potential drug interactions with dietary supplements.

5. Conclusions and Future Perspectives

Royal jelly is widely used for various medical and commercial purposes. Its biologically active compounds lend this natural product various pharmaceutical applications, with **very few side effects**. Accumulating evidence from the most recent studies indicated that **royal jelly possesses a significant role in modulating the mechanisms of natural aging**. This product has demonstrated its **efficiency in the alleviation of postmenopausal complaints**. Furthermore, it could be successfully used by postmenopausal women as a dietary supplement for the **treatment of aging-related pathologies, such as neurodegenerative diseases, diabetes, obesity, cancer, osteoporosis or cardiovascular pathology**. Unfortunately, there is only a small amount of clinical trials on humans regarding the effects of royal jelly in the postmenopausal period, the main majority being conducted on animal models. We consider that this paper paves the way for further investigations in the field. In our opinion it is very important to investigate whether and through which mechanisms **royal jelly could improve sleep disorders, hot flushes, postmenopausal headache, anxiety or depression**. Furthermore, the doses and the period of administration represent a topic of maximum interest because it can significantly influence the final results. Therefore, further clinical trials are imperative in order to elucidate the real value of this natural product as food supplement during menopause.

Author Contributions

Conceptualization, C.V.A.; methodology, L.D.; software, S.T.; validation, M.A.M., L.D., C.V.A.; data curation, A.E.N.; writing—original draft preparation, A.B.; visualization, S.T.; supervision, L.D. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Conflicts of Interest

The authors declare no conflict of interest.

References

1. McEniery, C.M. Transitioning the Menopause. *ATVB* **2020**, *40*, 850–852. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)]
2. Brzezinski, A. Menopausal symptoms: Not just estrogen deficiency. *Menopause* **2019**, *26*, 229–230. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)] [[PubMed](#)]
3. Rymer, J.; Wilson, R.; Ballard, K. Making decisions about hormone replacement therapy. *BMJ* **2003**, *326*, 322–326. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)] [[PubMed](#)]
4. Humphries, K.H.; Gill, S. Risks and benefits of hormone replacement therapy: The evidence speaks. *Can. Med. Assoc. J.* **2003**, *168*, 1001–1010. [[Google Scholar](#)]
5. Fernandez, E.; Gallus, S.; Bosetti, C.; Franceschi, S.; Negri, E.; Vecchia, C. Hormone replacement therapy and cancer risk: A systematic analysis from a network of case-control studies. *Int. J. Cancer* **2003**, *105*, 408–412. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)] [[PubMed](#)]
6. Beck, V.; Rohr, U.; Jungbauer, A. Phytoestrogens derived from red clover: An alternative to estrogen replacement therapy? *J. Steroid Biochem. Mol. Biol.* **2005**, *94*, 499–518. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)]
7. Pasupuleti, V.R.; Samugam, L.; Ramesh, N.; Gan, S.H. Honey, propolis, and royal jelly: A comprehensive review of their biological actions and health benefits. *Oxi. Med. Cell. Long.* **2017**, *2017*, 1259510. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)]
8. Li, J.; Feng, M.; Begna, D.; Fang, Y.; Zheng, A. Proteome comparison of hypopharyngeal gland development between Italian and royal jelly-producing worker honeybees (*Apis mellifera* L.). *J. Proteom. Res.* **2010**, *9*, 6578–6594. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)]
9. Viuda-Martos, M.; Ruiz-Navajas, Y.; Fernandez-Lopez, J.; Perez-Alvarez, J.A. Functional properties of honey, propolis, and royal jelly. *J. Food Sci.* **2008**, *73*, R117–R124. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)]

10. Cao, L.F.; Zheng, H.Q.; Pirk, C.W.; Hu, F.L.; Xu, Z.W. High Royal Jelly-Producing Honeybees (*Apis mellifera ligustica*) (Hymenoptera: Apidae) in China. *J. Econ. Entomol.* **2016**, *109*, 510–514. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)]
11. Altaye, S.Z.; Meng, L.; Li, J. Molecular insights into the enhanced performance of royal jelly secretion by a stock of honeybee (*Apis mellifera ligustica*) selected for increasing royal jelly production. *Apidologie* **2019**, *50*, 436–453. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)]
12. Altaye, S.Z.; Meng, L.; Lu, Y.; Li, J. The emerging proteomic research facilitates in-depth understanding of the biology of honeybees. *Int. J. Mol. Sci.* **2019**, *20*, 4252. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)] [[PubMed](#)]
13. Sig, A.K.; Öz-Sığ, Ö.; Güney, M. Royal jelly: A natural therapeutic? *Ortadogu Tip Derg* **2019**. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)]
14. Bogdanov, S. Royal Jelly, Bee Brood: Composition, Nutrition, Health. In *Encyclopedia of Insects*; Elsevier: Amsterdam, The Netherlands, 2016. [[Google Scholar](#)]
15. Kunugi, H.; Mohammed Ali, A. Royal Jelly and Its Components Promote Healthy Aging and Longevity: From Animal Models to Humans. *Int. J. Mol. Sci.* **2019**, *20*, 4662. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)] [[PubMed](#)]
16. Aludatt, M.; Rababah, T.; Sakandar, H.; Imran, M.; Mustafa, N.; Alhamad, M.; Mhaidat, N.; Kubow, S.; Tranchant, C.; Al Tawaha, A.R.; et al. Fermented food-derived bioactive compounds with anticarcinogenic properties: Fermented royal jelly as a novel source of compounds with health benefits. In *Anticancer Plants: Properties and Application*; Springer: Berlin/Heidelberg, Germany, 2018; pp. 141–165. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)]
17. Ramanathan, A.N.K.G.; Nair, A.J.; Sugunan, V.S. A review on royal jelly proteins and peptides. *J. Funct. Foods* **2018**, *44*, 255–264. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)]
18. Khazaei, M.; Ansarian, A.; Ghanbari, E. New findings on biological actions and clinical applications of royal jelly: A review. *J. Diet. Suppl.* **2017**, *15*, 757–775. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)]
19. Furusawa, T.; Rakwal, R.; Nam, H.W.; Shibato, J.; Agrawal, G.K.; Kim, Y.S.; Ogawa, Y.; Yoshida, Y.; Kouzuma, Y.; Masuo, Y.; et al. Comprehensive royal jelly (RJ) proteomics using one- and two-dimensional proteomics platforms reveals novel RJ proteins and potential phospho/glycoproteins. *J. Proteome Res.* **2008**, *7*, 3194–3229. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)]
20. Kamakura, M. Royalactin induces queen differentiation in honeybees. *Nature* **2011**, *473*, 478–483. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)]
21. Zhang, L.; Han, B.; Li, R.; Lu, X.; Nie, A.; Guo, L.; Fang, Y.; Feng, M.; Li, J. Comprehensive identification of novel proteins and N-glycosylation sites in royal jelly. *BMC Genomics* **2014**, *15*, 135. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)]
22. Han, B.; Fang, Y.; Feng, M.; Lu, X.; Huo, X.; Meng, L.; Wu, B.; Li, J. In-depth phosphoproteomic analysis of royal jelly derived from western and eastern honeybee species. *J. Proteome Res.* **2014**, *13*, 5928–5943. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)]
23. Bulet, P.; Stocklin, R. Insect antimicrobial peptides: Structures, properties and gene regulation. *Protein Peptide Lett.* **2005**, *12*, 3–11. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)] [[PubMed](#)]
24. Xue, X.; Wu, L.; Wang, K. Chemical composition of royal jelly. In *Bee Products—Chemical and Biological Properties*; Alvarez-Suarez, J.M., Ed.; Springer International Publishing: Cham, Switzerland, 2017; pp. 181–190. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)]
25. D'Antona, G.; Ragni, M.; Cardile, A.; Tedesco, L.; Dossena, M.; Bruttini, F.; Caliaro, F.; Corsetti, G.; Bottinelli, R.; Carruba, M.O.; et al. Branched-chain amino acid supplementation promotes survival and supports cardiac and skeletal muscle mitochondrial biogenesis in middle-aged mice. *Cell Metab.* **2010**, *12*, 362–372. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)]
26. Nagai, T.; Inoue, R. Preparation and functional properties of water extract and alkaline extract of royal jelly. *Food Chem.* **2004**, *84*, 181–186. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)]
27. Asencot, M.; Lensky, Y. The effect of sugars and juvenile hormone on the differentiation of the female honeybee larvae (*Apis mellifera* L.) to queens. *Life Sci.* **1976**, *18*, 693–699. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)]
28. Terada, Y.; Narukawa, M.; Watanabe, T. Specific hydroxy fatty acids in royal jelly activate TRPA1. *J. Agric. Food Chem.* **2011**, *59*, 2627–2635. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)] [[PubMed](#)]
29. Isidorov, V.A.; Bakier, S.; Grzech, I. Gas chromatographic–mass spectrometric investigation of volatile and extractable compounds of crude royal jelly. *J. Chromat.* **2012**, *885–886*, 109–116. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)] [[PubMed](#)]
30. Šedivá, M.; Laho, M.; Kohútová, L.; Mojžišová, A.; Majtán, J.; Klaudivy, J. 10-HDA, a major fatty acid of royal jelly, exhibits pH dependent growth-inhibitory activity against different strains of *Paenibacillus* larvae. *Molecules* **2018**, *23*, 3236. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)]
31. Suzuki, K.-M.; Isohama, Y.; Maruyama, H.; Yamada, Y.; Narita, Y.; Ohta, S.; Araki, Y.; Miyata, T.; Mishima, S. Estrogenic activities of fatty acids and a sterol isolated from royal jelly. *Evid. Complement. Alternat. Med.* **2008**, *5*, 295–302. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)]
32. Stocker, A.; Schramel, P.; Kettrup, A.; Bengsch, E. Trace and mineral elements in royal jelly and homeostatic effects. *J. Trace Elem. Med. Biol.* **2005**, *19*, 183–189. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)]
33. Hattori, N.; Nomoto, H.; Fukumitsu, H.; Mishima, S.; Furukawa, S. AMP N1-Oxide, a unique compound of royal jelly, induces neurite outgrowth from PC12 Vells via signaling by protein kinase a independent of that by mitogen-activated protein kinase. *Evid. Complement. Alternat. Med.* **2010**, *7*, 970174. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)]

34. Hattori, N.; Nomoto, H.; Mishima, S.; Inagaki, S.; Goto, M.; Sako, M.; Furukawa, S. Identification of AMP N1-oxide in royal jelly as a component neurotrophic toward cultured rat pheochromocytoma PC12 cells. *Biosci. Biotechnol. Biochem.* **2006**, *70*, 897–906. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)] [[PubMed](#)]
35. Wei, W.; Wei, M.; Kang, X.; Deng, H.; Lu, Z. A novel method developed for acetylcholine detection in royal jelly by using capillary electrophoresis coupled with electrogenerated chemiluminescence based on a simple reaction. *Electrophoresis* **2009**, *30*, 1949–1952. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)] [[PubMed](#)]
36. López-Gutiérrez, N.; Aguilera-Luiz, M.d.M.; Romero-González, R.; Vidal, J.L.M.; Garrido Frenich, A. Fast analysis of polyphenols in royal jelly products using automated TurboFlow™-liquid chromatography–Orbitrap high resolution mass spectrometry. *J. Chromat. B* **2014**, *973*, 17–28. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)] [[PubMed](#)]
37. Koya-Miyata, S.; Okamoto, I.; Ushio, S.; Iwaki, K.; Ikeda, M.; Kurimoto, M. Identification of a collagen production-promoting factor from an extract of royal jelly and its possible mechanism. *Biosci. Biotechnol. Biochem.* **2004**, *68*, 767–773. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)]
38. Ito, S.; Nitta, Y.; Fukumitsu, H.; Soumiya, H.; Ikeno, K.; Nakamura, T.; Furukawa, S. Antidepressant-like activity of 10-hydroxy-trans-2-decenoic Acid, a unique unsaturated Fatty Acid of royal jelly, in stress-inducible depression-like mouse model. *Evid. Complement. Alternat. Med.* **2012**, *2012*, 139140. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)] [[PubMed](#)]
39. Matsubara, T.; Sugimoto, H.; Aida, M. A Theoretical insight into the interaction of fatty acids involved in royal jelly with the human estrogen receptor β . *Bull. Chem. Soc. Jpn.* **2008**, *81*, 1258–1266. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)]
40. Moutsatsou, P.; Papoutsis, Z.; Kassi, E.; Heldring, N.; Zhao, C.; Tsiapara, A.; Melliou, E.; Chrousos, G.P.; Chinou, I.; Karshikoff, A.; et al. Fatty acids derived from royal jelly are modulators of estrogen receptor functions. *PLoS ONE* **2010**, *5*, e15594. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)]
41. Yang, X.Y.; Yang, D.S.; Wei, Z.; Wang, J.M.; Li, C.Y.; Hui, Y.; Lei, K.F.; Chen, X.F.; Shen, N.H.; Jin, L.Q.; et al. 10-Hydroxy-2-decenoic acid from royal jelly: A potential medicine for RA. *J. Ethnopharmacol.* **2010**, *128*, 314–321. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)]
42. Guo, H.; Kouzuma, Y.; Yonekura, M. Structure of properties of antioxidative peptides derived from royal jelly protein. *Food Chem.* **2009**, *113*, 238–245. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)]
43. Kashima, Y.; Kanematsu, S.; Asai, S.; Kusada, M.; Watanabe, S.; Kawashima, T.; Nakamura, T.; Shimada, M.; Goto, T.; Nagaoka, S. Identification of a novel hypocholesterolemic protein, major royal jelly protein 1, derived from royal jelly. *PLoS ONE* **2014**, *9*, e105073. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)]
44. Taebi, M.; Abdolalian, S.; Ozgoli, G.; Ebadi, A.; Kariman, N. Strategies to improve menopausal quality of life: A systematic review. *J. Edu. Health Prom.* **2018**, *7*, 93. [[Google Scholar](#)]
45. Mishima, S.; Suzuki, K.-M.; Isohama, Y.; Kuratsu, N.; Araki, Y.; Inoue, M.; Miyata, T. Royal jelly has estrogenic effects in vitro and in vivo. *J. Ethnopharmacol.* **2005**, *101*, 215–220. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)]
46. Eshtiyaghi, M.; Deldar, H.; Pirsaraei, Z.A.; Shohreh, B. Royal jelly may improve the metabolism of glucose and redox state of ovine oocytes matured in vitro and embryonic development following in vitro fertilization. *Theriogenology* **2016**, *86*, 2210–2221. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)]
47. Husein, M.Q.; Kridli, R.T. Reproductive responses following royal jelly treatment administered orally or intramuscularly into progesterone-treated Awassi ewes. *Anim. Reprod. Sci.* **2002**, *74*, 45–53. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)]
48. Imai, M.; Qin, J.; Yamakawa, N.; Miyado, K.; Umezawa, A.; Takahashi, Y. Molecular alterations during female reproductive aging: Can aged oocytes remind youth? *J. Embriol.* **2012**. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)]
49. Taavoni, S.; Barkhordari, F.; Goushegiri, A.; Haghani, H. Effect of royal jelly on premenstrual syndrome among Iranian medical sciences students: A randomized, triple-blind, placebo-controlled study. *Complement. Ther. Med.* **2014**, *22*, 601–606. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)]
50. Seyyedi, F.; Rafiean-Kopaei, M.; Miraj, S. Comparison of the effects of vaginal royal jelly and vaginal estrogen on quality of life, sexual and urinary function in postmenopausal women. *J. Clin. Diagn. Res.* **2016**, *10*, QC01. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)]
51. Sharif, S.N.; Darsareh, F. Effect of royal jelly on menopausal symptoms: A randomized placebo-controlled clinical trial. *Complement. Ther. Clin. Pract.* **2019**, *37*, 47–50. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)] [[PubMed](#)]
52. Asama, T.; Matsuzaki, H.; Fukushima, S.; Tatefuji, T.; Hashimoto, K.; Takeda, T. Royal jelly supplementation improves menopausal symptoms such as backache, low back pain, and anxiety in postmenopausal Japanese women. *Evid. Complement. Alternat. Med.* **2018**, *2018*, 4868412. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)] [[PubMed](#)]
53. Mofid, B.; Rezaeizadeh, H.; Termos, A.; Rakhsha, A.; Mafi, A.R.; Taheripanah, T.; Ardakani, M.M.; Taghavi, S.M.E.; Moravveji, S.A.; Kashi, A.S.Y. Effect of processed honey and royal jelly on cancer-related fatigue: A double-blind randomized clinical trial. *Electr. Phys.* **2016**, *8*, 2475–2482. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)] [[PubMed](#)]
54. Takayanagi, S.; Tokunaga, T.; Liu, X.; Okada, H.; Matsushima, A.; Shimohigashi, Y. Endocrine disruptor bisphenol A strongly binds to human estrogen-related receptor gamma (ERRgamma) with high constitutive activity. *Toxicol. Lett.* **2006**, *167*, 95–105. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)] [[PubMed](#)]
55. Nakaya, M.; Onda, H.; Sasaki, K.; Yukiyoishi, A.; Tachibana, H.; Yamada, K. Effect of royal jelly on bisphenol a-induced proliferation of human breast cancer cells. *Biosci. Biotechnol. Biochem.* **2007**, *71*, 253–255. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)] [[PubMed](#)]
56. Salazar-Olivo, L.A.; Paz-González, V. Screening of biological activities present in honeybee (*Apis mellifera*) royal jelly. *Toxicol. Vitro.* **2005**, *19*, 645–651. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)] [[PubMed](#)]

57. Shirzad, M.; Kordyazdi, R.; Shahinfard, N.; Nikokar, M. Does royal jelly affect tumor cells? *J. HerbMed. Pharmacol.* **2013**, *2*, 45–48. [[Google Scholar](#)]
58. Kamakura, M.; Moriyama, T.; Sakaki, T. Changes in hepatic gene expression associated with the hypocholesterolaemic activity of royal jelly. *J. Pharm. Pharmacol.* **2006**, *58*, 1683–1689. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)] [[PubMed](#)]
59. Lambrinoudaki, I.; Augoulea, A.; Rizos, D.; Politi, M.; Tsoltos, N.; Moros, M.; Chinou, I.; Graikou, K.; Kouskouni, E.; Kambani, S.; et al. Greek-origin royal jelly improves the lipid profile of postmenopausal women. *Gynecol. Endocrinol.* **2016**, *32*, 835–839. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)]
60. Guo, H.; Saiga, A.; Sato, M.; Miyazawa, I.; Shibata, M.; Takahata, Y.; Morimatsu, F. Royal jelly supplementation improves lipoprotein metabolism in humans. *J. Nutr. Sci. Vitaminol.* **2007**, *53*, 345–348. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)]
61. Hadi, A.; Najafgholizadeh, A.; Aydenlu, E.S.; Shafiei, Z.; Pirivand, F.; Golpour, S.; Pourmasoumi, M. Royal jelly is an effective and relatively safe alternative approach to blood lipid modulation: A meta-analysis. *J. Funct. Food.* **2018**, *41*, 202–209. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)]
62. Tokunaga, K.-H.; Yoshida, C.; Suzuki, K.-M.; Maruyama, H.; Futamura, Y.; Araki, Y.; Mishima, S. Antihypertensive effect of peptides from royal jelly in spontaneously hypertensive rats. *Biol. Pharm. Bull.* **2004**, *27*, 189–192. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)]
63. Pan, Y.; Rong, Y.; You, M.; Ma, Q.; Chen, M.; Hu, F. Royal jelly causes hypotension and vasodilation induced by increasing nitric oxide production. *Food Sci. Nutr.* **2019**, *7*, 1361–1370. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)]
64. Ensrud, K.E.; Crandall, C.J. Bisphosphonates for postmenopausal osteoporosis. *JAMA* **2019**, *322*, 2017–2018. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)] [[PubMed](#)]
65. Shimizu, S.; Matsushita, H.; Minami, A.; Kanazawa, H.; Suzuki, T.; Watanabe, K.; Wakatsuki, A. Royal jelly does not prevent bone loss but improves bone strength in ovariectomized rats. *Climacteric* **2018**, *21*, 601–606. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)] [[PubMed](#)]
66. Hidaka, S.; Okamoto, Y.; Uchiyama, S.; Nakatsuma, A.; Hashimoto, K.; Ohnishi, T.; Yamaguchi, M. Royal jelly prevents osteoporosis in rats: Beneficial effects in ovariectomy model and in bone tissue culture model. *Evid. Complement. Alternat. Med.* **2006**, *3*, 580958. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)]
67. Okumura, N.; Toda, T.; Ozawa, Y.; Watanabe, K.; Ikuta, T.; Tatefuji, T.; Hashimoto, K.; Shimizu, T.J.N. Royal jelly delays motor functional impairment during aging in genetically heterogeneous male mice. *Nutrients* **2018**, *10*, 1191. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)]
68. Xin, X.-X.; Chen, Y.; Chen, D.; Xiao, F.; Parnell, L.D.; Zhao, J.; Liu, L.; Ordovas, J.M.; Lai, C.-Q.; Shen, L.-R. Supplementation with major royal-jelly proteins increases lifespan, feeding, and fecundity in drosophila. *J. Agric. Food Chem.* **2016**, *64*, 5803–5812. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)] [[PubMed](#)]
69. Detienne, G.; De Haes, W.; Ernst, U.R.; Schoofs, L.; Temmerman, L. Royalactin extends lifespan of *Caenorhabditis elegans* through epidermal growth factor signaling. *Exp. Gerontol.* **2014**, *60*, 129–135. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)]
70. Ji, W.; Zhang, C.; Wei, W.; Hu, F. The in vivo antiaging effect of enzymatic hydrolysate from royal jelly in d-galactose induced aging mouse. *J. Chin. Inst. Food Sci. Technol.* **2016**, *16*, 18–25. [[Google Scholar](#)] [[CrossRef](#)]
71. Honda, Y.; Araki, Y.; Hata, T.; Ichihara, K.; Ito, M.; Tanaka, M.; Honda, S. 10-Hydroxy-2-decenoic Acid, the major lipid component of royal jelly, extends the lifespan of *Caenorhabditis elegans* through dietary restriction and target of rapamycin signaling. *J. Aging Res.* **2015**, *2015*, 425261. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)]
72. Zheng, J.; Lai, W.; Zhu, G.; Wan, M.; Chen, J.; Tai, Y.; Lu, C. 10-Hydroxy-2-decenoic acid prevents ultraviolet A-induced damage and matrix metalloproteinases expression in human dermal fibroblasts. *J. Eur. Acad. Dermatol. Venerol.* **2013**, *27*, 1269–1277. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)]
73. Park, H.M.; Hwang, E.; Lee, K.G.; Han, S.-M.; Cho, Y.; Kim, S.Y. Royal jelly protects against ultraviolet B-induced photoaging in human skin fibroblasts via enhancing collagen production. *J. Med. Food.* **2011**, *14*, 899–906. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)]
74. Jiang, C.-M.; Liu, X.; Li, C.-X.; Qian, H.-C.; Chen, D.; Lai, C.-Q.; Shen, L.-R. Anti-senescence effect and molecular mechanism of the major royal jelly proteins on human embryonic lung fibroblast (HFL-I) cell line. *J. Zhejiang Univ.* **2018**, *19*, 960–972. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)] [[PubMed](#)]
75. Raine-Fenning, N.J.; Brincat, M.P.; Muscat-Baron, Y. Skin aging and menopause. *Am. J. Clin. Dermatol.* **2003**, *4*, 371–378. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)] [[PubMed](#)]
76. Park, H.M.; Cho, M.H.; Cho, Y.; Kim, S.Y. Royal jelly increases collagen production in rat skin after ovariectomy. *J. Med. Food* **2012**, *15*, 568–575. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)]
77. Henderson, V.W. The neurology of menopause. *Neurology* **2006**, *12*, 149–159. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)]
78. Zamani, Z.; Reisi, P.; Alaei, H.; Pilehvarian, A.A. Effect of royal jelly on spatial learning and memory in rat model of streptozotocin-induced sporadic Alzheimer's disease. *Adv. Biomed. Res.* **2012**, *1*, 26. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)] [[PubMed](#)]
79. Cihan, Y.; Arsav, V.; Göcen, E. Royal jelly in the prevention of radiation-induced brain damages. *J. Neurol. Sci.* **2012**, *28*, 475–486. [[Google Scholar](#)]
80. Zhang, X.; Yu, Y.; Sun, P.; Fan, Z.; Zhang, W.; Feng, C. Royal jelly peptides: Potential inhibitors of β -secretase in N2a/APP695swe cells. *Sci. Rep.* **2019**, *9*, 168. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)]

81. Pyrzanowska, J.; Piechal, A.; Blecharz-Klin, K.; Joniec-Maciejak, I.; Graikou, K.; Chinou, I.; Widy-Tyszkiewicz, E. Long-term administration of Greek Royal Jelly improves spatial memory and influences the concentration of brain neurotransmitters in naturally aged Wistar male rats. *J. Ethnopharmacol.* **2014**, *155*, 343–351. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)]
82. Minami, A.; Matsushita, H.; Ieno, D.; Matsuda, Y.; Horii, Y.; Ishii, A.; Takahashi, T.; Kanazawa, H.; Wakatsuki, A.; Suzuki, T. Improvement of neurological disorders in postmenopausal model rats by administration of royal jelly. *Climacteric* **2016**, *19*, 568–573. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)] [[PubMed](#)]
83. Münstedt, K.; Bargello, M.; Hauenschild, A. Royal jelly reduces the serum glucose levels in healthy subjects. *J. Med. Food.* **2009**, *12*, 1170–1172. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)]
84. Yoshida, M.; Hayashi, K.; Watadani, R.; Okano, Y.; Tanimura, K.; Kotoh, J.; Sasaki, D.; Matsumoto, K.; Maeda, A. Royal jelly improves hyperglycemia in obese/diabetic KK-Ay mice. *J. Vet. Med. Sci.* **2017**, *79*, 299–307. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)] [[PubMed](#)]
85. Zamami, Y.; Takatori, S.; Goda, M.; Koyama, T.; Iwatani, Y.; Jin, X.; Takai-Doi, S.; Kawasaki, H. Royal jelly ameliorates insulin resistance in fructose-drinking rats. *Biol. Pharm. Bull.* **2008**, *31*, 2103–2107. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)] [[PubMed](#)]
86. Ghanbari, E.; Nejati, V.; Azadbakht, M. Protective effect of royal jelly against renal damage in streptozotocin induced diabetic rats. *Iran J. Toxicol.* **2015**, *9*, 1258–1263. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)]
87. Maleki, V.; Jafari-Vayghan, H.; Saleh-Ghadimi, S.; Adibian, M.; Kheirouri, S.; Alizadeh, M. Effects of Royal jelly on metabolic variables in diabetes mellitus: A systematic review. *Complement. Ther. Med.* **2019**, *43*, 20–27. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)]
88. Kaczor, M.; Koltek, A.; Matuszewski, J. Effect of royal jelly on blood lipids in atherosclerosis. *Polski Tygodnik Lekarski.* **1962**, *17*, 1140–1144. [[Google Scholar](#)]
89. Mobasser, M.; Pourmoradian, S.; Mahdavi, R.; Faramarzi, E. Effects of royal jelly supplementation on lipid profile and high-sensitivity c-reactive protein levels in type-2 diabetic women: A pilot study. *Curr. Top. Nutr. Res.* **2014**, *12*, 101–106. [[Google Scholar](#)]
90. Mobasser, M.; Ghiyasvand, S.; Ostadrahimi, A.; Ghojaziadeh, M.; Noshad, H.; Pourmoradian, S. Effect of fresh royal jelly ingestion on glycemic response in patients with type 2 diabetes. *Iranian Red Crescent Med. J.* **2015**, *17*, e20074. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)]
91. Shidfar, F.; Jazayeri, S.; Mousavi, S.N.; Malek, M.; Hosseini, A.F.; Khoshpey, B. Does supplementation with royal jelly improve oxidative stress and insulin resistance in type 2 diabetic patients? *Iran. J. Public Health.* **2015**, *44*, 797–803. [[Google Scholar](#)]
92. Chiu, H.-F.; Chen, B.-K.; Lu, Y.-Y.; Han, Y.-C.; Shen, Y.-C.; Venkatakrishnan, K.; Golovinskaia, O.; Wang, C.-K. Hypocholesterolemic efficacy of royal jelly in healthy mild hypercholesterolemic adults. *Pharm. Biol.* **2017**, *55*, 497–502. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)]
93. Petelin, A.; Kenig, S.; Kopinč, R.; Deželak, M.; Černelič Bizjak, M.; Jenko Pražnikar, Z.; Medicine, A. Effects of royal jelly administration on lipid profile, satiety, inflammation, and antioxidant capacity in asymptomatic overweight adults. *J. Evid. Complement.* **2019**, *2019*, 4969720. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)]
94. Takai-Doi, S.; Hashimoto, K.; Yamamura, M.; Kamei, C. Antihypertensive activities of royal jelly protein hydrolysate and its fractions in spontaneously hypertensive rats. *Acta Med. Okayama.* **2009**, *63*, 57–64. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)] [[PubMed](#)]
95. Kaku, M.; Rocabado, J.M.R.; Kitami, M.; Ida, T.; Uoshima, K. Royal jelly affects collagen crosslinking in bone of ovariectomized rats. *J. Funct. Food.* **2014**, *7*, 398–406. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)]
96. Chen, D.; Liu, F.; Wan, J.-B.; Lai, C.-Q.; Shen, L.-R. Effect of major royal jelly proteins on spatial memory in aged rats: Metabolomics analysis in urine. *J. Agric. Food Chem.* **2017**, *65*, 3151–3159. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)]
97. Sefirin, D.; Nange, A.C.; Florette, M.T.; Franklin, Z.G.; Florence, A.C.; Pierre, K.; Dieudonné, N. Royal jelly induced anxiolytic effects and prevent hot flushes in a menopausal model on wistar rat. *J. Biomed. J. Sci. Tech. Res.* **2019**, *19*, 14557–14566. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)]
98. Liu, X.; Chen, Y.; Shen, L. Protective effects of major royal jelly proteins on reproductive function of mice during perimenopausal period. *Agric. Life Sci.* **2019**, *45*, 751–759. [[Google Scholar](#)] [[CrossRef](#)]
99. You, M.M.; Liu, Y.C.; Chen, Y.F.; Pan, Y.M.; Miao, Z.N.; Shi, Y.Z.; Si, J.J.; Chen, M.L.; Hu, F.L. Royal jelly attenuates nonalcoholic fatty liver disease by inhibiting oxidative stress and regulating the expression of circadian genes in ovariectomized rats. *J. Food Biochem.* **2020**, *44*, e13138. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)] [[PubMed](#)]
100. Rosmilah, M.; Shahnaz, M.; Patel, G.; Lock, J.; Rahman, D.; Masita, A.; Noormalin, A. Characterization of major allergens of royal jelly *Apis mellifera*. *J. Trop. Biomed.* **2008**, *25*, 243–251. [[Google Scholar](#)]
101. Yonei, Y.; Shibagaki, K.; Tsukada, N.; Nagasu, N.; Inagaki, Y.; Miyamoto, K.; Suzuki, O.; Kiryu, Y. Case report: Haemorrhagic colitis associated with royal jelly intake. *Gastroenterol. Hepatol.* **1997**, *12*, 495–499. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)] [[PubMed](#)]
102. Katayama, M.; Aoki, M.; Kawana, S. Case of anaphylaxis caused by ingestion of royal jelly. *J. Dermatol.* **2008**, *35*, 222–224. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)] [[PubMed](#)]
103. Paola, F.; Pantalea, D.D.; Gianfranco, C.; Antonio, F.; Angelo, V.; Eustachio, N.; Elisabetta, D.L. Oral allergy syndrome in a child provoked by royal jelly. *Case Rep. Med.* **2014**, *2014*, 941248. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)]

104. Lee, N.J.; Fermo, J.D. Warfarin and royal jelly interaction. *Pharmacotherapy* **2006**, *26*, 583–586. [[Google Scholar](#)] [[CrossRef](#)] [[Scilit](#)] [[PubMed](#)]